NantKwest
San Diego · Founded 2002
About NantKwest
NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment of virally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma.
Company Facts
- Founded: 2002
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $103.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2019)
- Ticker: nasdaq:NK
- Website: nantkwest.com
- Phone: (858)633-0300
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nantkwest-156591 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.